Abstract:e13575 Background: Homologous recombination deficiency (HRD) can be resulted from dysfunction of BRCA and is associated with sensitivity to platinum, PARP inhibitor and other DNA-damaging drugs. The results from a neoadjuvant trial showed that pathological complete response (pCR) was not significantly higher with cisplatin than with doxorubicin-cyclophosphamide in BRCA1/2-mutated breast cancers (BC). It suggests that BC with HRD might benefit from anthracycline-containing regiment. There are many commercial HRD detection assays, including the FoundationFocus CDx BRCA LOH and myChoice CDx, but there is still no uniform standard in China. Methods: A total of 96 in-house BC samples and 6 HRD positive standard cells (Cat No. CBP90023) were analyzed by whole-genome sequencing (WGS). Besides, 122 BCs from the TCGA database were down-sampled to ̃1X WGS. We constructed a new algorithm for HRD score based on WGS at low coverage as input data to estimate large-scale copy number alteration (LCNA) events on the genome. The sensitivity and specificity were compared between our algorithm and the ShallowHRD. A clinical cohort of 50 BCs (15 cases carrying BRCA mutation) was used to assess the association between HRD status and anthracyclines-containing neoadjuvant treatment outcomes. Results: A 100kb-window was defined as the optimal size by using 41 in-house cases and the TCGA dataset. The threshold of HRD was determined as the number of 10 LCNAs by using 55 in-house BCs with BRCA mutation, with the goal of achieving 95% sensitivity. The sensitivity and specificity of our algorithm were both 100%, while those of the ShallowHRD were 40% and 100%, respectively, by testing standard samples with positive HRD. Meanwhile, similar results were also observed that the sensitivity of our algorithm was far superior to ShallowHRD (87% vs 13%) in the clinical cohort. The association between HRD status and BRCA mutations was compared between our algorithm and the ShallowHRD by 120 BC WGS samples (20 cases carrying BRCA mutation) from the TCGA database. The results showed that BRCA status was significantly associated with HRD status by our algorithm and ShallowHRD (P = 0.00838 and P = 0.00284, respectively). However, our algorithm had a higher positive concordance rate than the ShallowHRD algorithm (70% vs 60%). In the clinical cohort of neoadjuvant treatment, HRD group was more likely to respond to anthracycline-containing chemotherapy than non-HRD group, with outcomes of pCR (OR = 9.5, 95% CI: 1.11–81.5, p = 0.04) and residual cancer burden score of 0 or 1 (RCB0/1) (OR = 10.29, 95% CI: 2.02–52.36, p = 0.005). Among 35 patients lacking BRCA mutations, HRD group tended to have RCB0/1 responses compared to non-HRD group (OR = 6.0, 95% CI: 1.00–35.91, p = 0.05). Conclusions: Here, we developed a new stable algorithm for HRD score. It's a promising assay for clinical application to predict sensitivity of DNA-damaging drugs.

A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer

Abstract PS4-46: Homologous Recombination Deficiency Score Predicts Patient Characteristics and Outcomes of Triple Negative Breast Cancer in China

TP53 -specific mutations serve as a potential biomarker for homologous recombination deficiency in breast cancer: a clinical next-generation sequencing study

Association between Homologous Recombination Repair Defect Status and Long-Term Prognosis of Early HER2-Low Breast Cancer: A Retrospective Cohort Study

Identification of a Hypoxia-Related Molecular Classification and Hypoxic Tumor Microenvironment Signature for Predicting the Prognosis of Patients with Triple-Negative Breast Cancer

Association Between Homologous Recombination Deficiency Status and Carboplatin Treatment Response in Early Triple-Negative Breast Cancer

Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency

Genomic and molecular landscape of homologous recombination deficiency across multiple cancer types

Radiogenomics of homologous recombination deficiency (HRD) in breast cancer: Radiomics-based image biomarker for HRD.

Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

Association of tumor immune infiltration and prognosis with homologous recombination repair genes mutations in early triple-negative breast cancer

Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score

Pan-cancer Analysis Reveals Homologous Recombination Deficiency Score As a Predictive Marker for Immunotherapy Responders

Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer.

CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors

Clinical and molecular significance of homologous recombination deficiency positive non-small cell lung cancer in Chinese population: An integrated genomic and transcriptional analysis

A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients

Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (Tx).

Development of a new HRD algorithm which was highly associated with anthracycline-containing neoadjuvant chemotherapy.